Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future Trials

被引：17

作者：

Bonnan, Mickael ^{[1
]}

Ferrari, Sylvie ^{[2
]}

Bertandeau, Eric ^{[1
]}

Demasles, Stephanie ^{[1
]}

Krim, Elsa ^{[1
]}

Miquel, Marie ^{[1
]}

Barroso, Bruno ^{[1
]}

机构：

[1] Hop F Mitterrand, Serv Neurol, F-64046 Pau, France

[2] Hop F Mitterrand, F-64046 Pau, France

来源：

CURRENT DRUG TARGETS | 2014年 / 15卷 / 13期

关键词：

Chronic progressive; intrathecal injection; lymphoma; multiple sclerosis; rituximab; CENTRAL-NERVOUS-SYSTEM; EPSTEIN-BARR-VIRUS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; DOSE IMMUNOSUPPRESSIVE THERAPY; CEREBRAL PERIVASCULAR SPACES; FLUID COMPLEMENT ACTIVATION; STEM-CELL TRANSPLANTATION; PRIMARY CNS LYMPHOMA; LIVED PLASMA-CELLS; CEREBROSPINAL-FLUID;

D O I：

10.2174/1389450115666141029234644

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Rituximab has demonstrated a major effect in B-cell lymphoma and in a wide range of autoimmune disorders. Unfortunately, the blood-brain-barrier excludes the disorders restricted to the central nervous system (CNS) from the action of rituximab. The progressive phase of multiple sclerosis (MS) is a prototypical CNS autoimmune disorder characterized by an intrathecal compartmentalization of inflammation resisting all the available immunosuppressive treatments. As a consequence, intrathecal therapeutics are promising new approach in progressive MS. We first review data gathered from animal models and human off-label intrathecal rituximab use in CNS lymphomas, then summarize the recent evidence supporting the need for trials based on the intrathecal use of rituximab in multiple sclerosis. The experience obtained in these settings offers valuable preliminary data for future studies in CNS autoimmunity.

引用

页码：1205 / 1214

页数：10

共 108 条

[1] Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look [J].